ZVRA Q3 2020 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$559M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-83.2% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$1M-63.0% margin

Net Income

-$3M-156.3% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

-72.1%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$385,000

Balance Sheet

Total Assets

$11M

Total Liabilities

$74M

Stockholders' Equity

-$62M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$11M	-83.2%
Gross Profit	$2M	$10M	-81.6%
Operating Income	-$1M	$3M	-137.5%
Net Income	-$3M	$3M	-210.8%